<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The feasibility and effects of combination chemotherapy for very elderly patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> was examined in 65 patients (including previous <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) aged 76 years or morewith a performance status of 0 - 3 </plain></SENT>
<SENT sid="1" pm="."><plain>Induction chemotherapy was performed with 30 mg/m2 daunorubicin on days 1 - 3, 150 mg/m2 behenoyl <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> on days 1 - 7, and 70 mg/m2 <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> with 300 mg <z:chebi fb="0" ids="40279">allopurinol</z:chebi> taken orally on days 1 - 7 (BHAC-DM) </plain></SENT>
<SENT sid="2" pm="."><plain>The complete remission (CR) rate was 38.5%, whereas overall survival at 2 and 5 years was 22.0% and 4.7%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Two- and 5-year survival of CR patients was 41.8% and 11.2%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The relapse rate of the 25 CR patients was 64.0% and disease-free survival at 2 and 5 years was 21.0% and 11.2%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The therapy-related mortality rate at induction was 13.8% </plain></SENT>
<SENT sid="6" pm="."><plain>BHAC-DM is feasible and effective for selected very elderly <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> patients </plain></SENT>
</text></document>